Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a pioneering company in the field of drug delivery technology. The company has developed and patented a unique drug delivery platform known as DehydraTECH™, which enhances the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. This technology is notable for significantly improving bio-absorption rates, reducing the onset time of drugs, and masking unpleasant tastes.
DehydraTECH™ has demonstrated remarkable efficacy in enhancing the bio-absorption of cannabinoids and nicotine, increasing their uptake by 5-10 times, and in some cases, by as much as 27 times compared to traditional formulations. This technology also shows potential in improving the delivery of certain drugs through the blood-brain barrier, making it particularly valuable for drugs targeting the central nervous system.
The company operates four key segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. Intellectual Property Licensing is the primary revenue generator for Lexaria, leveraging its robust portfolio of 43 granted patents and numerous pending patents worldwide.
Lexaria's recent endeavors include a series of human and animal studies focused on the application of DehydraTECH™ in enhancing the delivery and efficacy of GLP-1 drugs. These drugs, such as semaglutide and tirzepatide, are primarily used for treating diabetes and promoting weight loss. The company has partnered with the National Research Council of Canada (NRC) to investigate the molecular characteristics and performance of DehydraTECH-processed GLP-1 drugs.
The latest human pilot studies have shown promising results, including higher drug delivery and better blood glucose control with fewer side effects. The company is also exploring the use of DehydraTECH™ for other APIs like cannabidiol (CBD), with applications in treating hypertension and epilepsy.
Recent financial activities include a warrant exercise agreement, raising approximately $4.7 million, which bolsters Lexaria's operational runway into 2025. This financial stability allows the company to pursue its aggressive research and development plans.
Lexaria's innovative approach and continuous research efforts position it as a significant player in the drug delivery technology sector, with the potential to form strategic partnerships with leading pharmaceutical companies.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announces the appointment of Gregory Downey as the new Chief Financial Officer effective April 15, 2021. Downey, previously the Company's Controller, brings over ten years of CFO experience and will be compensated with a CDN$144,000 annual salary, a 10% increase, and stock options. The Company also plans to issue 300,000 share purchase warrants to third-party consultants, exercisable until April 16, 2024, at US$9.00 per share. Lexaria continues to advance its DehydraTECH technology for improved drug delivery.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announced that its client Amari Corp.'s "Everyday Calm" CBD product was recognized as a Top CBD Product Pick by New Hope Network during the Natural Products Expo 2020. This accolade underscores the effectiveness of Lexaria's DehydraTECH technology, which enhances CBD delivery for improved consumer satisfaction. The DehydraTECH platform demonstrates a potential increase in bio-absorption by up to 10x, essential for the growth of CBD products in retail. Lexaria aims to expand the reach of its technology across multiple product formats.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announced its largest-ever R&D initiative for 2021, targeting four drug markets with a potential value of $87 billion. The studies will focus on enhancing delivery systems for NSAIDs, THC, nicotine, and sildenafil using the DehydraTECH technology. Key market insights include the NSAID market expected to grow to $24.4 billion by 2027 and the cannabis market projected at $40.6 billion by 2024. These initiatives aim to improve drug absorption and speed, with test articles scheduled for manufacturing and dosing in the coming months.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced successful stability testing for its DehydraTECHTM CBD-infused beverages, revealing a remarkable 93.4% potency retention one year post-production. This ensures excellent microbial purity and consistent CBD distribution without physical mixing, addressing common beverage degradation challenges. The technology, which significantly enhances cannabinoid absorption, is poised for broader applications, and Lexaria continues its industry leadership in innovative drug delivery systems.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) is advancing its hypertension research and development program, which includes three human clinical studies and two animal studies, alongside two antiviral drug evaluations. CEO Chris Bunka will present at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 9:45 AM ET, detailing the company's DehydraTECH drug delivery technology aimed at improving the bio-absorption of active pharmaceutical ingredients. Lexaria holds 18 granted patents and approximately 60 pending, positioning itself strongly in the biotech sector.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reports progress in two of four planned antiviral studies using its DehydraTECH™ technology targeting SARS-CoV-2. The studies assess the effectiveness of enhanced formulations of antiviral drugs, including Remdesivir, in animal and human cell cultures. Results from the animal study (VIRAL-A20-2) are expected by late May, while human cell evaluations (VIRAL-C21-3) will commence in April, with results anticipated in June. The entire research initiative is fully funded and aims for regulatory approvals and commercial partnerships.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced advancements in five studies investigating DehydraTECHTM CBD as a treatment for hypertension. This includes three human clinical trials and two animal studies. The studies aim to evaluate CBD's absorption rates and its potential effects on blood pressure. Initial results from animal studies are expected by May, while human trial findings are anticipated by September. Lexaria, holding 18 international patents, aims to leverage these studies for potential commercial opportunities in the $28 billion annual hypertension market.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has expanded its hypertension R&D program, now including three human clinical studies and two animal studies to assess the effectiveness of DehydraTECH-processed CBD. CEO Chris Bunka will present at the 33rd Annual Virtual ROTH Conference from March 15-17, 2021, discussing the innovative DehydraTECH drug delivery technology that enhances bio-absorption of active pharmaceutical ingredients. The conference will host numerous companies and attract over 5,000 attendees, presenting a unique opportunity for investors.
Lexaria Bioscience (NASDAQ: LEXX) has raised $11 million to support its research and development (R&D) strategy focusing on its patented DehydraTECH technology. This technology enhances the bioavailability of drugs, particularly in the treatment of hypertension and antiviral therapies. The company is set to conduct clinical studies on a CBD formulation aimed at lowering blood pressure and is working on improving antiviral drug delivery against COVID-19. CEO Chris Bunka highlights the significant market potential, with hypertension alone representing a $30 billion industry.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has expanded its 2021 hypertension research program, now consisting of five studies aimed at evaluating DehydraTECH-processed CBD. This includes three human clinical studies (HYPER-H21-1, HYPER-H21-2, HYPER-H21-3) and two animal studies (HYPER-A21-1, HYPER-A21-2). The studies are designed to assess the efficacy of CBD on blood pressure, with initial dosing expected in early March. Lexaria aims for growth through partnerships in the hypertension and CBD pharmaceutical markets, supported by their robust patent portfolio.
FAQ
What is the current stock price of Lexaria Bioscience (LEXX)?
What is the market cap of Lexaria Bioscience (LEXX)?
What is Lexaria Bioscience Corp. known for?
How does DehydraTECH™ improve drug delivery?
What are the main business segments of Lexaria?
What recent achievements has Lexaria accomplished?
What are some key applications of DehydraTECH™?
How many patents does Lexaria hold?
What partnerships has Lexaria recently engaged in?
What financial activities has Lexaria recently undertaken?
How does DehydraTECH™ benefit centrally active compounds?
Where can I find more information about Lexaria?
